Successful Treatment of Refractory Gastrointestinal Bleeding by Systemic (Oral) Ankaferd Blood Stopper in a Patient with Glanzmann Thrombasthenia

Yıl 2015, Cilt: 32 Sayı: 2, 218 - 220, 01.04.2015

Sibel Kabukçu Hacıoğlu Mehmet Hilmi Doğu İsmail Sarı Ali Keskin

Öz

Background: Glanzmann Thrombasthenia (GT) is a genetic platelet dysfunction and a life threatening disease. Ankaferd Blood Stopper (ABS) is a topical hemostatic agent of herbal origin which has been recently made available for clinical use. Its hemostatic effect is independent from blood clotting factors and occurs as a result of the aggregation of focal red blood cells by an encapsulated protein web. Case Report: In this paper, a patient with GT is presented in whom 3 months of gastrointestinal bleeding refractory to all medical therapies was controlled within a short time of using oral ABS. Conclusion: The difference between this patient and other cases presented in the medical literature is the oral use of ABS. Thus, this patient may contribute to the medical community in showing the safety and efficacy of systemic (oral) ABS in patients with disorders of coagulation. However, there is a need for more patient experiences.

Anahtar Kelimeler

Ankaferd Blood Stopper, disorders of hemostasis, Glanzmann thrombasthenia, oral systemic administration

Kaynakça

• 1. Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010;41:1-6. [CrossRef]
• 2. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010;15:329-36.
• 3. Beyazit Y, Kekilli M, Haznedaroglu IC, Kayacetin E, Basaranoglu M. Ankaferd hemostat in the management of gastrointestinal hemorrhages. World J Gastroenterol 2011;17:3962-70. [CrossRef]
• 4. Beyazit Y, Kart T, Kuscu A, Arslan A, Kurt M, Aktas B, et al. Successful management of bleeding after dental procedures with application of blood stopper: a single center prospective trial. J Contemp Dent Pract 2011;12:379-84. [CrossRef]
• 5. Bakdash S, Lyons JM, Bastacky SI, Pezzone MA, McGee JB, Schoen RE, et al. Management of persistent gastric bleeding in a patient with Glanzmann’s thrombasthenia. Am J Hematol 2008;83:411-5. [CrossRef]
• 6. Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A. Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. Indian J Pediatr 2011;78:961-8. [CrossRef]
• 7. Kazancıoğlu HO, Cakır O, Ak G, Zülfikar B. The Effectiveness of a New Hemostatic Agent (Ankaferd Blood Stopper) for the Control of Bleeding following Tooth Extraction in Hemophilia: A Controlled Clinical Trial. Turk J Haematol 2013;30:19-24. [CrossRef]
• 8. Baykul T, Alanoglu EG, Kocer G. Use of Ankaferd Blood Stopper as a hemostatic agent: a clinical experience. J Contemp Dent Pract 2010;11:88-94.
• 9. Solak Y, Gaipov A, Ozbek O, Hassan MA, Yeksan M. Massive haematuria successfully managed by intravesical Ankaferd in a haemodialysis patient complicated with disseminated intravascular coagulation. BMJ Case Rep 2012;2012.
• 10. Ozseker B, Shorbagi A, Efe C, Haznedaroglu IC, Bayraktar Y. Controlling of upper gastrointestinal bleeding associated with severe immune thrombocytopenia via topical adjunctive application of Ankaferd blood stopper. Blood Coagul Fibrinolysis 2012;23:464. [CrossRef]
• 11. SonmezM,BaltacioğluE,SaracO,ErkutN.The use ofAnkaferd blood stopper in a patient with Glanzmann’s thrombasthenia with gingival bleeding. Blood Coagul Fibrinolysis 2010;21:382-83. [CrossRef]
• 12. Leblebisatan G, Bay A, Karakus SC, Kekilli M, Haznedaroglu IC. Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis. Blood Coagul Fibrinolysis 2012;23:494-97. [CrossRef]
• 13. Akbal E, Köklü S, Astarcı HM, Koçak E. Oral high-dose ankaferd administration effects on gastrointestinal system. Int J Med Sci 2013;10:451-6. [CrossRef]
• 14. Kurt M, Oztas E, Kuran S, Onal IK, Kekilli M, Haznedaroglu IC. Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability. Am J Emerg Med 2009;27:631. [CrossRef]